Cat No.
CEI-0208
Description
Semagacestat (LY450139) can inhibit gamma-secretase such as, Abeta42, Abeta40 and Abeta38, with IC50 of 10.9 nM, 12.1 nM and 12.0 nM.
CAS No.
425386-60-3
Targets
Abeta42, Abeta40, Abeta38
Chemical Name
(S)-2-hydroxy-3-methyl-N-((S)-1-((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ylamino)-1-oxopropan-2-yl)butanamide
M.Wt
361.44
Purity
>99%
Solubility
DSMO 72 mg/mL Water
Storage
2 years at -20 centigrade
In vitro
Semagacestat (LY450139) is a novel, smallmolecular weight inhibitor of gamma-secretase inhibitor. This inhibitor is developed for treating Alzheimers disease (AD), which is a progressive neurodegenerative disease.
In vivo
Oral administration of Semagacestat (1 mg/kg) to 5.5-month old APP-transgenic Tg2576 mice significantly ameliorates memory deficits on spatial working memory using the Y-maze task, which disappears after 8 days subchronic dosing.
